HLS Therapeutics (HLS) Aperçu de l'action
HLS Therapeutics Inc. est une société pharmaceutique spécialisée qui acquiert et commercialise des produits pharmaceutiques pour le traitement des troubles psychiatriques, du système nerveux central et des maladies cardiovasculaires au Canada, aux États-Unis et dans le monde entier. Plus de détails
| Score flocon de neige | |
|---|---|
| Évaluation | 3/6 |
| Croissance future | 4/6 |
| Performances passées | 0/6 |
| Santé financière | 3/6 |
| Dividendes | 0/6 |
HLS Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
HLS Therapeutics Inc. Concurrents
Historique des prix et performances
| Historique des cours de bourse | |
|---|---|
| Prix actuel de l'action | CA$4.42 |
| Plus haut sur 52 semaines | CA$5.77 |
| Plus bas sur 52 semaines | CA$4.11 |
| Bêta | 0.85 |
| Variation sur 1 mois | -4.74% |
| Variation sur 3 mois | 0.68% |
| Variation sur 1 an | -10.53% |
| Variation sur 3 ans | -28.36% |
| Variation sur 5 ans | -74.00% |
| Évolution depuis l'introduction en bourse | -61.86% |
Nouvelles et mises à jour récentes
Mise à jour du récit • Jun 23
HLS: Future Upside Will Depend On Executing Reaffirmed 2026 Earnings Guidance
Analysts have adjusted their CA$5 price target on HLS Therapeutics in light of updated assumptions for revenue growth, profit margins, and future P/E. This reflects a refined view of the stock's potential value.
Mise à jour du récit • Jun 07
HLS: Future Execution Risks Will Restrain Benefits Of New Franchise And Hold Stance
Analysts have updated their view on HLS Therapeutics with a refined fair value of CA$4.49 per share. This is supported by refreshed assumptions on revenue growth, profit margins, discount rate and future P/E that align with recent Street price targets in the CA$4.45 to CA$5.00 range.Mise à jour du récit • May 24
HLS: Future Upside Will Depend On Delivering New 2026 Revenue Guidance
Analysts have modestly adjusted their CA$ price target on HLS Therapeutics, with models reflecting a fair value estimate holding close to CA$12.00, supported by recent Hold-rated coverage and slightly lower Street targets around CA$4.45 to CA$5.00. Analyst Commentary Recent Street research on HLS Therapeutics has centered on Hold ratings paired with price targets in the CA$4.45 to CA$5.00 range.Recent updates
Mise à jour du récit • Jun 23
HLS: Future Upside Will Depend On Executing Reaffirmed 2026 Earnings Guidance
Analysts have adjusted their CA$5 price target on HLS Therapeutics in light of updated assumptions for revenue growth, profit margins, and future P/E. This reflects a refined view of the stock's potential value.Mise à jour du récit • Jun 07
HLS: Future Execution Risks Will Restrain Benefits Of New Franchise And Hold Stance
Analysts have updated their view on HLS Therapeutics with a refined fair value of CA$4.49 per share. This is supported by refreshed assumptions on revenue growth, profit margins, discount rate and future P/E that align with recent Street price targets in the CA$4.45 to CA$5.00 range.Mise à jour du récit • May 24
HLS: Future Upside Will Depend On Delivering New 2026 Revenue Guidance
Analysts have modestly adjusted their CA$ price target on HLS Therapeutics, with models reflecting a fair value estimate holding close to CA$12.00, supported by recent Hold-rated coverage and slightly lower Street targets around CA$4.45 to CA$5.00. Analyst Commentary Recent Street research on HLS Therapeutics has centered on Hold ratings paired with price targets in the CA$4.45 to CA$5.00 range.Mise à jour du récit • May 04
HLS: Future Upside Will Depend On Executing Refined Earnings Outlook
Analysts have trimmed their price target on HLS Therapeutics to CA$4.45 from CA$4.75, reflecting updated views on the company that feed into revised assumptions regarding growth, margins and future P/E. Analyst Commentary Recent research updates on HLS Therapeutics show price targets aligning at CA$4.45, with ratings maintained rather than shifted to more negative stances.Mise à jour du récit • Apr 18
HLS: Future Execution Risks Will Temper Benefits Of New Cholesterol Franchise
Analysts have trimmed their price target on HLS Therapeutics to CA$4.45 from CA$4.75, reflecting updated views on its growth profile and profitability. Analyst Commentary Bearish analysts are signaling a more cautious stance on HLS Therapeutics after the revised CA$4.45 price target.Mise à jour du récit • Apr 02
HLS: Future Execution Risks Will Offset New Product And Margin Assumptions
Analysts have trimmed their price target on HLS Therapeutics to CA$4.45 from CA$4.75, reflecting updated views on the company’s revenue growth potential, profit margin outlook, and a higher assumed future P/E multiple. Analyst Commentary Bearish analysts have reacted to recent developments by trimming their price target on HLS Therapeutics to CA$4.45 from CA$4.75, while maintaining a Hold stance.Mise à jour du récit • Mar 18
HLS: Future Share Performance Will Rely On Execution Against Updated Outlook
The analyst price target for HLS Therapeutics has been reduced by CA$0.30 to CA$4.45. Analysts cited updated assumptions around growth, profitability and valuation multiples as key drivers for the change.Mise à jour du récit • Mar 03
HLS: Fair Outlook Will Balance Revised Profitability Assumptions And Execution Risks
Analysts have trimmed their price target on HLS Therapeutics to CA$4.72 from CA$4.76, reflecting updated assumptions around discount rates, revenue growth, profit margins, and a slightly lower future P/E multiple. Valuation Changes Fair Value: CA$ fair value estimate adjusted slightly from CA$4.76 to CA$4.72.Mise à jour du récit • Feb 17
HLS: Improved Profitability Outlook Will Support Stronger Future Share Performance
Analysts now see fair value for HLS Therapeutics at about CA$11.59, slightly below the prior CA$11.79. This reflects updated assumptions around discount rate, revenue growth, profit margin and future P/E expectations.Mise à jour du récit • Feb 03
HLS: Higher Profitability Outlook Will Support Upgraded Future Share Performance
Analysts have nudged their price target on HLS Therapeutics higher to C$7 from C$6, pointing to updated assumptions on revenue growth, profit margins and future P/E levels that support a slightly revised outlook for the shares. Analyst Commentary Recent Street research reflects a slightly more optimistic tone around HLS Therapeutics, with bullish analysts adjusting their models to support a higher valuation anchor for the shares.Mise à jour du récit • Jan 20
HLS: Higher Profitability Outlook Will Drive Stronger Future Share Performance
Analysts have raised their price target on HLS Therapeutics to C$7 from C$6, reflecting updated views on fair value, growth expectations, profitability, and future P/E assumptions. Analyst Commentary Recent Street research points to a more constructive view on HLS Therapeutics, with bullish analysts revisiting their assumptions on fair value, growth potential, and what they are willing to pay on a P/E basis.Mise à jour du récit • Jan 06
HLS: Higher Rating Outlook Will Balance Execution Risks And Near Term Guidance
Analysts lifted their price target for HLS Therapeutics to C$7 from C$6, citing updated assumptions around fair value, discount rate, revenue growth, profit margins and a lower future P/E multiple in their models. Analyst Commentary Even with the price target now set at C$7, some research commentary still reads as cautious.Mise à jour du récit • Dec 14
HLS: Higher Projected Earnings Will Support Stronger Future Share Performance
Analysts have raised their price target on HLS Therapeutics by C$1 to C$7, reflecting higher projected fair value, faster expected revenue growth, and improved profit margin assumptions, despite a slightly higher discount rate and lower future P/E multiple. Analyst Commentary Bullish analysts highlight that the higher price target reflects growing confidence in HLS Therapeutics execution and earnings trajectory, even after factoring in a modestly higher risk profile.
Mise à jour du récit • Nov 19
HLS: Ongoing Share Buybacks And Debt Reduction Will Drive Positive Momentum
The analyst price target for HLS Therapeutics has increased from C$6 to C$7. This reflects analysts’ confidence in the company’s improving financial performance and ongoing strategic initiatives.Article d’analyse • Nov 16
HLS Therapeutics Inc. (TSE:HLS) Just Reported, And Analysts Assigned A CA$6.80 Price Target
The analysts might have been a bit too bullish on HLS Therapeutics Inc. ( TSE:HLS ), given that the company fell short...Mise à jour du récit • Sep 25
Canadian Regulatory Approvals Will Foster A Vibrant Cardiovascular Market
Analysts have raised their price target for HLS Therapeutics to CA$7.41, citing positive impacts from share buybacks, debt reduction, and an expanding product portfolio, alongside signs of adjusted EBITDA recovery and improved operational performance. Analyst Commentary Share buybacks and debt reduction are viewed positively for capital allocation and balance sheet strength.
Nouveau récit • Apr 07
Vascepa Sales In Canada And Cost Cuts Will Transform Prospects
Significant revenue growth is expected from Vascepa in Canada, driven by increased prescriptions and stabilizing payer mix, positively impacting revenue.Article d’analyse • Oct 26
Are Investors Undervaluing HLS Therapeutics Inc. (TSE:HLS) By 45%?
Key Insights Using the 2 Stage Free Cash Flow to Equity, HLS Therapeutics fair value estimate is CA$6.42 Current share...Article d’analyse • Sep 28
Pinning Down HLS Therapeutics Inc.'s (TSE:HLS) P/S Is Difficult Right Now
It's not a stretch to say that HLS Therapeutics Inc.'s ( TSE:HLS ) price-to-sales (or "P/S") ratio of 1.5x right now...Article d’analyse • May 12
Analysts Have Lowered Expectations For HLS Therapeutics Inc. (TSE:HLS) After Its Latest Results
It's shaping up to be a tough period for HLS Therapeutics Inc. ( TSE:HLS ), which a week ago released some...Article d’analyse • Apr 14
After Leaping 29% HLS Therapeutics Inc. (TSE:HLS) Shares Are Not Flying Under The Radar
The HLS Therapeutics Inc. ( TSE:HLS ) share price has done very well over the last month, posting an excellent gain of...Article d’analyse • Apr 06
Here's Why HLS Therapeutics (TSE:HLS) Can Afford Some Debt
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Article d’analyse • Nov 16
Analysts Are More Bearish On HLS Therapeutics Inc. (TSE:HLS) Than They Used To Be
Market forces rained on the parade of HLS Therapeutics Inc. ( TSE:HLS ) shareholders today, when the analysts...Article d’analyse • Sep 13
Here's Why HLS Therapeutics (TSE:HLS) Can Afford Some Debt
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Article d’analyse • May 05
Would HLS Therapeutics (TSE:HLS) Be Better Off With Less Debt?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Article d’analyse • Apr 05
HLS Therapeutics (TSE:HLS) Is Due To Pay A Dividend Of $0.05
The board of HLS Therapeutics Inc. ( TSE:HLS ) has announced that it will pay a dividend on the 15th of June, with...Article d’analyse • Mar 20
HLS Therapeutics (TSE:HLS) Is Paying Out A Dividend Of $0.05
The board of HLS Therapeutics Inc. ( TSE:HLS ) has announced that it will pay a dividend on the 15th of June, with...Rendement pour les actionnaires
| HLS | CA Pharmaceuticals | CA Marché | |
|---|---|---|---|
| 7D | 0.7% | -2.7% | -1.5% |
| 1Y | -10.5% | 52.5% | 31.3% |
Rendement vs Industrie: HLS a sous-performé le secteur Canadian Pharmaceuticals qui a rapporté 52.5 % au cours de l'année écoulée.
Rendement vs marché: HLS a sous-performé le marché Canadian qui a rapporté 31.3 % au cours de l'année écoulée.
Volatilité des prix
| HLS volatility | |
|---|---|
| HLS Average Weekly Movement | 2.7% |
| Pharmaceuticals Industry Average Movement | 10.5% |
| Market Average Movement | 9.8% |
| 10% most volatile stocks in CA Market | 16.6% |
| 10% least volatile stocks in CA Market | 3.7% |
Cours de l'action stable: HLS n'a pas connu de volatilité de prix significative au cours des 3 derniers mois par rapport au marché Canadian.
Volatilité au fil du temps: La volatilité hebdomadaire de HLS ( 3% ) est restée stable au cours de l'année écoulée.
À propos de l'entreprise
| Fondée | Salariés | PDG | Site web |
|---|---|---|---|
| n/a | 85 | Craig Millian | www.hlstherapeutics.com |
HLS Therapeutics Inc. est une société pharmaceutique spécialisée qui acquiert et commercialise des produits pharmaceutiques pour le traitement des troubles psychiatriques, du système nerveux central et des maladies cardiovasculaires au Canada, aux États-Unis et dans le monde entier. Les principaux produits de la société sont Clozaril, un antipsychotique atypique pour la gestion des symptômes de la schizophrénie résistante au traitement, et Vascepa, une capsule d'icosapent éthyle pour les maladies cardiovasculaires. Elle distribue également les tests de laboratoire MyCare pour la psychiatrie et MyCare Insite, un dispositif de mesure des niveaux de médicaments sur le lieu de soins.
HLS Therapeutics Inc. Résumé des fondamentaux
| HLS statistiques fondamentales | |
|---|---|
| Capitalisation boursière | CA$139.80m |
| Bénéfices(TTM) | -CA$14.61m |
| Recettes(TTM) | CA$79.14m |
1.7x
Ratio P/S-9.5x
Ratio P/ELe site HLS est-il surévalué ?
Voir Juste valeur et analyse de l'évaluationBénéfices et recettes
| HLS compte de résultat (TTM) | |
|---|---|
| Recettes | US$55.74m |
| Coût des recettes | US$16.15m |
| Marge brute | US$39.59m |
| Autres dépenses | US$49.89m |
| Les revenus | -US$10.29m |
Derniers bénéfices déclarés
Mar 31, 2026
Prochaine date de publication des résultats
s/o
| Résultat par action (EPS) | -0.33 |
| Marge brute | 71.03% |
| Marge bénéficiaire nette | -18.46% |
| Ratio dettes/capitaux propres | 73.5% |
Quelles ont été les performances à long terme de HLS?
Voir les performances historiques et les comparaisonsAnalyse de l'entreprise et données financières
| Données | Dernière mise à jour (heure UTC) |
|---|---|
| Analyse de l'entreprise | 2026/06/23 11:10 |
| Cours de l'action en fin de journée | 2026/06/23 00:00 |
| Les revenus | 2026/03/31 |
| Revenus annuels | 2025/12/31 |
Sources de données
Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC. Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.
| Paquet | Données | Cadre temporel | Exemple de source américaine * |
|---|---|---|---|
| Finances de l'entreprise | 10 ans |
| |
| Estimations consensuelles des analystes | +3 ans |
|
|
| Prix du marché | 30 ans |
| |
| Propriété | 10 ans |
| |
| Gestion | 10 ans |
| |
| Principaux développements | 10 ans |
|
* Exemple pour les titres américains ; pour les titres non américains, des formulaires réglementaires et des sources équivalentes sont utilisés.
Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). En savoir plus.
Modèle d'analyse et flocon de neige
Les détails du modèle d'analyse utilisé pour générer ce rapport sont disponibles sur notre page Github, nous proposons également des guides pour apprendre à utiliser nos rapports et des tutoriels sur YouTube.
Découvrez l'équipe de classe mondiale qui a conçu et construit le modèle d'analyse Simply Wall St.
Indicateurs de l'industrie et du secteur
Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur Github.
Sources des analystes
HLS Therapeutics Inc. est couverte par 4 analystes. 4 de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.
| Analyste | Institution |
|---|---|
| David Martin | Bloom Burton & Co. |
| Tania Armstrong-Whitworth | Canaccord Genuity |
| Michael Freeman | Raymond James Ltd. |